This white paper explains how biopharma teams can accelerate their BLA pathway by adopting modern, high‑throughput analytical strategies for complex biologics— combining Lonza’s platform experience, advanced tools like MAM and automated glycan analytics, and early CQA co‑creation to create valuable insights that improve consistency and speed on your way to BLA readiness.
You may also be interested in:
Mammalian
Fabs, Fusion, Scaffold and other Recombinant Proteins
Bispecific Antibody
Process Development and Optimization
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.
Latest briefing from the Knowledge Center
Blog
Inhalable mRNA lipid nanoparticle powders via spray drying: is it possible?
Dry powder inhaled formulations of small molecule drugs are a mainstay of treatment for respiratory...
Webinar (on-demand)
Cracking Complexity: Learnings from 70+ Bispecific Antibody Programs
The biologics pipeline is becoming increasingly complex as next generation antibody formats,...
Webinar (on-demand)
Accelerating Success: Advanced Developability Strategies for Bioconjugates ​and ADCs
In this on-demand webinar, our experts explore how Lonza’s Early Development Services support...
Webinar (on-demand)
The 24 Months Before CGT Launch
Every second counts: what real cell and gene therapy launches teach us For cell and gene...
Webinar (on-demand)
Faster Clones, Simpler Process: What’s Changing in CHO Expression?
This webinar will discuss the latest innovation in the GS® Expression System. We will discuss how...
Webinar (on-demand)
In Vivo CAR-T And Gene Editing: The Manufacturing Reality Behind The Promise
In vivo CAR-T is moving fast, and so are the manufacturing challenges behind it. LNPs and viral...
White paper
Avoiding the Pitfalls: Five Lessons for Cell Therapy Manufacturing Success
This white paper explores five common manufacturing and operational challenges that can delay or...
Article
Expert Q&A: Navigating Complexity in Modern Small Molecule Development
Interview with our Lonza subject matter expert in small molecule development.
Webinar (on-demand)
Early Developability Assessment for Antibody-based Therapeutics
In this on-demand webinar, Head of Immunology, Noel Smith, PhD, explores how our integrated toolbox...
Webinar (on-demand)
From Insights to Impact: Predictive Models and PAT for More Efficient and Robust Biologics...
Scaling biologics from development to commercial manufacturing requires precision, consistency,...
Poster
Establishment of a High‑Yield Stable Producer Cell Line for CD19 Chimeric Antigen Receptor-Based...
Lentiviral vectors (LVVs) are increasingly needed for gene and cell therapies, but transient...
Poster
A Robust System for High-titer, Platform-agnostic AAV Production in HEK293 Cell Lines
Successful Adeno-Associated Virus (AAV) programs requires careful choosing of critical production...